Category: Include on Menu
-
Gold Prices Rise 1.5% as Dollar and US Treasury Yields Retreat
Gold prices advanced in Asian trading on Friday, supported by a weaker US dollar and declining Treasury yields, as investors assessed inflation risks linked to higher energy prices and the outlook for Federal Reserve monetary policy. Spot gold increased 1.5% to $4,218.15 per ounce, while US gold futures also gained 1.5% to $4,219.40. The precious…
-
Oil Prices Decline as Trump Comments on Iran Talks Ease Immediate Supply Concerns
Oil prices moved lower on Friday after US President Donald Trump indicated that Washington would not launch military strikes against Iran before November’s congressional midterm elections, easing some immediate concerns about further disruptions to Middle Eastern energy supplies. Brent crude futures fell 72 cents, or 0.7%, to $103.53 per barrel by 02:20 GMT. US West…
-
US Stock Futures Rise as Investors Assess OpenAI Revenue Reports, Delta Earnings and Consumer Sentiment: Dow Jones, S&P, Nasdaq, Wall Street
US stock futures moved higher on Friday as investors assessed differing reports about OpenAI’s revenue outlook, awaited quarterly results from Delta Air Lines and prepared for new consumer sentiment data. Developments in the Middle East, energy prices and telecommunications markets also remained in focus following a volatile session on Wall Street. At 03:04 ET (07:04…
-
Nasdaq Drops as OpenAI Revenue Report Rattles Chip Stocks and Oil Jumps
Wall Street ended mixed on Thursday, with technology shares dragging the Nasdaq and S&P 500 lower while the Dow Jones Industrial Average managed a small gain. Two forces drove the action: a sharp sell-off in semiconductor stocks after a report that OpenAI’s revenue is running well below earlier signals, and a jump in crude oil…
-
Buzbuzian Capital Completes $300,000 Strategic Investment in Getchell Gold’s Nevada Mining Opportunity
The investment gives Buzbuzian Capital exposure to Getchell Gold’s Fondaway Canyon project, which has a preliminary economic assessment outlining a US$1 billion pre-tax net present value and projected annual gold production of 150,000 ounces. Key Investor Takeaways Why GGLDF Stock Is in Focus Getchell Gold has secured a $300,000 investment from Canadian family office Buzbuzian…
-
China SXT Pharmaceuticals Announces $12 Million Registered Direct Offering With Significant Dilution Potential
China SXT Pharmaceuticals has agreed to sell 8 million shares at $1.50 each, alongside warrants containing a zero-cash exercise provision and an additional $12 million purchase option for institutional investors. Key Investor Takeaways Why SXTC Stock Is in Focus China SXT Pharmaceuticals has entered into a definitive securities purchase agreement with institutional investors for a…
-
DarkIris Prices $6 Million Public Offering at $1.44 Per Unit With Potential for Significant Share Dilution
DarkIris has announced a $6 million financing to support working capital and corporate operations, with a warrant structure that could substantially increase its outstanding share count. Key Investor Takeaways Why DKI Stock Is in Focus DarkIris has priced a best-efforts public offering expected to generate approximately $6 million in gross proceeds before placement agent fees…
-
Medicus Pharma Outlines Clinical Development Strategy Across Three Drug Programs Following $90 Million in Financing
Medicus Pharma is prioritizing clinical milestones, regulatory progress and potential partnerships across its oncology, dermatology and urology portfolio as it seeks to demonstrate returns on three years of investment. Key Investor Takeaways Why MDCX Stock Is in Focus Medicus Pharma has provided a three-year shareholder update detailing its transition from a company primarily focused on…
-
Sunshine Biopharma Prices $6 Million Public Offering at $0.55 Per Unit, Raising Dilution Concerns
The financing will provide additional working capital for Sunshine Biopharma, but the inclusion of two warrants per unit creates potential future share dilution for existing shareholders. Key Investor Takeaways Why SBFM Stock Is in Focus Sunshine Biopharma has announced the pricing of a public offering expected to generate approximately $6 million in gross proceeds through…
-
Femasys to Showcase FemaSeed Fertility Treatment at ASRM 2026 as Commercialization Strategy Expands
Femasys will present its fertility treatment and diagnostic portfolio at the ASRM 2026 Scientific Congress & Expo, highlighting its efforts to expand adoption across OB/GYN practices and reproductive endocrinology clinics. Key Investor Takeaways Why FEMY Stock Is in Focus Femasys has confirmed its participation in the American Society for Reproductive Medicine’s 2026 Scientific Congress &…